In this study, we first evaluated the effect of the dual target inhibitor NVP-BEZ235 on HCC, then explored the synergistic effect of IL-6 antibody combined with NVP-BEZ235 for the treatment of HCC. This evidence concerns the gene IL6 and hepatocellular carcinoma.